SAMIDORPHAN L-MALATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H26N2O4.C4H6O5
Molecular Weight	504.5306
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1CC1CN2CC[C@@]34CC(=O)CC[C@]4([C@@]2([H])Cc5ccc(c(c53)O)C(=N)O)O.C([C@@]([H])(C(=O)O)O)C(=O)O

InChI

InChIKey=RARHXUAUPNYAJF-QSYGGRRVSA-N

InChI=1S/C21H26N2O4.C4H6O5/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12;5-2(4(8)9)1-3(6)7/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26);2,5H,1H2,(H,6,7)(H,8,9)/t16-,20-,21-;2-/m10/s1

HIDE SMILES / InChI

Molecular Formula	C21H26N2O4
Molecular Weight	370.4429
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O5
Molecular Weight	134.0876
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01903837 | https://www.ncbi.nlm.nih.gov/pubmed/30188587 | https://www.ncbi.nlm.nih.gov/pubmed/30859977

Samidorphan was developed as a sublingually bioavailable µ-opioid receptor antagonist. This drug participated in clinical trials for the treatment of Schizophrenia, Alcohol Dependence, and Binge Eating Disorder. The oral dose pharmacokinetics, safety, and tolerability of samidorphan were evaluated in phase II double blind, placebo-controlled, randomized studies in healthy adults. In addition, the combination of samidorphan (SAM) with buprenorphine (BUP) was studied in phase III clinical trial in patients with major depressive disorder (MDM). It was shown that the long-term treatment did not reveal any new safety findings and confirmed that the risk of abuse and dependence with BUP/SAM was low.

Approval Year

PubMed

Title	Date	PubMed
		30859977
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.	2016 May 1	26869247
Evaluation of samidorphan, a μ-opioid antagonist, in a drug discrimination assay in rats.	2018 Aug	30188587
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.	2018 Oct	30055046

Patents

Sample Use Guides

In Vivo Use Guide

Samidorphan (Low Dose). Tablets taken once daily

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:24:15 UTC 2021` Edited by `admin` on `Fri Jun 25 21:24:15 UTC 2021`
Record UNII	0AJQ5N56E0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAMIDORPHAN L-MALATE

Official Name

English

LYBALVI COMPONENT SAMIDORPHAN L-MALATE

Brand Name

English

SAMIDORPHAN L-MALATE [WHO-DD]

Common Name

English

SAMIDORPHAN L-MALATE [USAN]

Common Name

English

MORPHINAN-3-CARBOXAMIDE, 17-(CYCLOPROPYLMETHYL)-4,14-DIHYDROXY-6-OXO-, (2S)-2-HYDROXYBUTANEDIOATE (1:1)

Common Name

English

SAMIDORPHAN L-MALATE COMPONENT OF LYBALVI

Brand Name

English

RDC-0313-02

Code

English

17-(CYCLOPROPYLMETHYL)-4,14-DIHYDROXY-6-OXOMORPHINAN-3-CARBOXAMIDE HYDROGEN (2S)-2-HYDROXYBUTANEDIOATE SALT

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C681